Document text
Principal Investigator: Nitin S Baliga
Organization: INSTITUTE FOR SYSTEMS BIOLOGY
Fiscal Year: 2021
Award: $76,331
Funding agency: National Institute of Allergy and Infectious Diseases
Project Summary
The NIAID national protocol intends to enroll at least 1000 COVID19 patients in a study designed to track infected
patients through tracking, over time, their immune responses, viral load, and a variety of multi-omic analytes that
can provide deep insights into how infection by SARS-CoV-2 is revealed in host defense responses and disease-
perturbed networks. At the heart of this study is the establishment of high quality biorepositories that can be
used to quantitatively assess viral load, quantitatively interrogate viable PBMCs, and permit direct comparisons
between different patients and different time points of disease progression. The nature of the infection, with
highly differential patient outcomes, will eventually require significant computational efforts that can account for
confounding factors such as co-morbidities, the influence of various therapies that are being broadly tested in
these patients, etc. It will also certainly require both broadly available immune characterization tools that can be
applied on all patient samples, but also specialized tools that can be used to inform the interpretation of the
general analytics. In this project, we propose to integrate two sets of immune cell characterizations into the
national NIAID effort. Those characterizations include single cell, functional phenotyping of select immune cell
classes via an analysis designed to quantitate the levels of 35 secreted proteins from up to 2000 single cells of
a given immune cell type. The second characterization is based upon reducing proteins from the SARS-CoV-2
into peptide antigen-major histocompatibility complex (pMHC) libraries that can be used to identify SARS-CoV-
2 antigen-specific CD8+ and CD4+ T cell populations from isolated, viable PBMCs. These assays provide deep
and complementary information that will significantly inform the interpretation of the immune phenotyping assays
that constitute the COREs of the NIAID study.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Alleles><Allelomorphs><Antibodies><Antigens><Assay><Bioassay><Biologic Assays><Biological Assay><Biotech><Biotechnology><Blood><Blood Reticuloendothelial System><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><COVID infected patient><COVID patient><COVID positive patient><COVID-19 antigen><COVID-19 assay><COVID-19 infected patient><COVID-19 infection><COVID-19 patient><COVID-19 positive patient><COVID-19 virus><COVID19 assay><COVID19 infection><COVID19 patient><COVID19 positive patient><COVID19 virus><Cell Body><Cells><Cellular Assay><Clinical><CoV-2><CoV2><Computing Methodologies><Coupled><DNA><Deoxyribonucleic Acid><Disease><Disease Progression><Disorder><Drugs><Enrollment><Funding><Heart><Histocompatibility Complex><Histocompatibility Complices><Host Defense><IRB><IRBs><Immune><Immune mediated therapy><Immune response><Immunes><Immunologic Subtyping><Immunological response><Immunologically Directed Therapy><Immunophenotyping><Immunotherapy><Infection><Institutes><Institutional Review Boards><Investigation><Investigators><Joints><LYT3><Label><Libraries><Link><Major Histocompatibility Complex><Major Histocompatibility Complices><Medical center><Medication><NIAID><National Institute of Allergy and Infectious Disease><Nature><PBMC><Participant><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Peptides><Peripheral Blood Mononuclear Cell><Pharmaceutic Preparations><Pharmaceutical Preparations><Phenotype><Population><Proteins><Protocol><Protocols documentation><RNA Seq><RNA sequencing><RNAseq><Receptor Protein><Reporting><Research Design><Research Personnel><Researchers><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 antigen><SARS-CoV-2 assay><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV2><SARS-CoV2 antigen><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Scanning><Scientist><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome related corona virus 2><Site><Study Type><Surface><Survey Instrument><Surveys><Systems Biology><T-Cell Receptor Genes><T-Cells><T-Lymphocyte><T4 Cells><T4 Lymphocytes><T8 Cells><T8 Lymphocytes><TcR Genes><Technology><Testing><Time><Viral Burden><Viral Load><Viral Load result><Work><Wuhan coronavirus><antigen-specific T cells><base><biobank><biorepository><cell assay><cell type><co-morbid><co-morbidity><cohort><comorbidity><computational methodology><computational methods><computer based method><computer methods><computing method><coronavirus disease 2019 antigen><coronavirus disease 2019 assay><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 virus><coronavirus disease infected patient><coronavirus disease patient><coronavirus disease positive patient><coronavirus patient><defense response><design><designing><drug/agent><enroll><hCoV19><host response><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunophenotype><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><insight><multiomics><multiple omics><nCoV2><nasal swab><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient response><patient specific response><patient subgroups><patient subpopulations><patient subsets><patient subtypes><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><physiological defense response><receptor><recruit><response><responsive patient><severe acute respiratory syndrome coronavirus 2 antigen><severe acute respiratory syndrome coronavirus 2 assay><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><study design><thymus derived lymphocyte><tool><transcriptome sequencing>